Journal
Journal of Clinical Investigation
Publication Date
8-1-2023
Volume
133
Issue
15
First Page
e163841
Document Type
Open Access Publication
DOI
10.1172/JCI163841
Rights and Permissions
Chen L, Shi V, Wang S, Sun L, Freeman R, Yang J, Inkman MJ, Ghosh S, Ruiz F, Jayachandran K, Huang Y, Luo J, Zhang J, Cosper P, Luke CJ, Spina CS, Grigsby PW, Schwarz JK, Markovina S. SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production. J Clin Invest. 2023 Aug 1;133(15):e163841. doi: 10.1172/JCI163841. © 2023, Chen et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Recommended Citation
Chen, Liyun; Shi, Victoria; Wang, Songyan; Sun, Lulu; Freeman, Rebecca; Yang, Jasmine; Inkman, Matthew J.; Ghosh, Subhajit; Ruiz, Fiona; Jayachandran, Kay; Huang, Yi; Luo, Jingqin; Zhang, Jin; Cosper, Pippa; Luke, Clifford J; Grigsby, Perry W.; Schwarz, Julie K.; Markovina, Stephanie; and et al., "SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production." Journal of Clinical Investigation. 133, 15. e163841 (2023).
https://digitalcommons.wustl.edu/oa_4/2119
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
